Skip to main content
Symptom
dx.
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Symptom
dx.
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Get Started
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Loading...
Nephrotic Syndrome Flare
Cardiovascular Presentations
Abdominal aortic aneurysm
Acute coronary syndrome (NSTEMI)
Acute coronary syndrome (STEMI)
Acute decompensated heart failure
Acute limb ischemia
Acute mesenteric ischemia
Aortic dissection
Aortic stenosis
Atrial fibrillation and flutter
Bradyarrhythmia and heart block
Cardiac arrest
Deep vein thrombosis
Myocarditis
Pericarditis
Pulmonary embolism
Stable angina
Superficial thrombophlebitis
Superior vena cava syndrome
Supraventricular tachycardia
Syncope (cardiogenic)
Unstable angina
Ventricular tachycardia
Respiratory Presentations
Acute bronchitis
Acute respiratory failure
Aspiration pneumonia
Asthma exacerbation
Bronchiolitis
Community-acquired pneumonia
COVID-19 pneumonia
COPD exacerbation
Croup
Croup (laryngotracheobronchitis)
Epiglottitis
Hemothorax
Hospital-acquired pneumonia
Pleural effusion
Pneumothorax (traumatic)
Pulmonary contusion
Spontaneous pneumothorax
Neurological Presentations
Bell's palsy
Benign paroxysmal positional vertigo
Brain abscess
Cauda equina syndrome
Cervical radiculopathy
Concussion (mild traumatic brain injury)
Encephalitis
Guillain-Barré syndrome
Hemorrhagic stroke (intracerebral)
Ischemic stroke
Lumbar radiculopathy
Malignant spinal cord compression
Migraine
Peripheral neuropathy (acute)
Retropharyngeal abscess
Schizophrenia (acute exacerbation)
Seizure (breakthrough:known epilepsy)
Seizure (first-time)
Spinal cord injury
Status epilepticus
Subarachnoid hemorrhage
Tension headache
Transient ischemic attack
Traumatic brain injury (moderate-severe)
Vestibular neuritis
Viral meningitis
Gastrointestinal Presentations
Acute appendicitis
Acute cholecystitis
Acute diverticulitis
Acute pancreatitis
Anal fissure
Choledocholithiasis and cholangitis
Clostridioides difficile colitis
Gastritis
Gastroenteritis (viral and bacterial)
Gastroesophageal reflux disease
Incarcerated or strangulated hernia
Inflammatory bowel disease flare
Large bowel obstruction
Lower GI hemorrhage
Peptic ulcer disease
Perforated viscus
Small bowel obstruction
Upper GI hemorrhage
Genitourinary and Reproductive Presentations
Acute prostatitis
Acute urinary retention
Ectopic pregnancy
Epididymitis
Orchitis
Ovarian torsion
Paraphimosis
Pelvic inflammatory disease
Priapism
Pyelonephritis
Renal laceration
Ruptured ovarian cyst
Testicular torsion
Tubo-ovarian abscess
Urinary tract infection (uncomplicated)
Urolithiasis (renal colic)
Vaginal bleeding (non-pregnant)
Infectious Disease Presentations
Acute sinusitis
Acute tonsillitis
Acute upper respiratory infection
Animal bite
Bacterial meningitis
Cellulitis
Conjunctivitis (bacterial)
Dental abscess
Endocarditis
Febrile neutropenia
Fournier gangrene
Hand-foot-mouth disease
Hepatitis (acute)
Herpes zoster
HIV-related illness
Human bite
Impetigo
Infected diabetic foot ulcer
Infectious mononucleosis
Influenza
Necrotizing fasciitis
Osteomyelitis
Otitis externa
Parasitic infection
Periorbital cellulitis
Peritonsillar abscess
Scabies
Sepsis
Septic arthritis
Spontaneous bacterial peritonitis
Tick-borne illness (Lyme disease)
Tinea infection
Tuberculosis
Viral exanthem
Wound infection
Trauma Presentations
Achilles tendon rupture
ACL and mceniscus tear
Ankle fracture
Ankle sprain
Burn
Calcaneus fracture
Cervical spine fracture
Clavicle fracture
Dental avulsion
Distal radius fracture
Drowning
Elbow fracture and dislocation
Electrical injury
Facial bone fracture
Facial laceration
Femur fracture
Fingertip amputation
Forearm fracture (radius and ulna)
Frostbite
Hand:finger laceration
Heat exhaustion
Heat stroke
Hip fracture
Humeral shaft fracture
Knee dislocation
Knee sprain
Lightning injury
Mandible fracture
Metacarpal fracture
Metatarsal fracture
Muscle strain
Nasal fracture
Non-accidental trauma
Orbital fracture
Patella fracture
Phalanx fracture (finger)
Proximal humerus fracture
Pulmonary contusion
Rib fracture
Rotator cuff tear (acute traumatic)
Scalp laceration
Scaphoid fracture
Shoulder dislocation
Skull fracture
Splenic laceration
Sternal fracture
Supracondylar pediatric fracture
Tendon laceration (hand:wrist)
Thoracic and lumbar spine fracture
Tibia:fibula fracture
Tibial plateau fracture
Toe fracture
Traumatic epistaxis
Traumatic hyphema
Toxicologic Presentations
Acetaminophen toxicity
Alcohol intoxication
Alcohol withdrawal
Anticholinergic toxicity
Anticoagulant overdose
Benzodiazepine overdose
Benzodiazepine:sedative overdose
Beta-blocker and calcium channel blocker toxicity
Carbon monoxide poisoning
Caustic ingestion
Digoxin toxicity
Drug eruption
Foreign body ingestion
Opioid intoxication
Opioid overdose
Opioid withdrawal
Organophosphate
Salicylate toxicity
Serotonin syndrome
Stimulant intoxication (cocaine, methamphetamine)
Tricyclic antidepressant overdose
Psychiatric Presentations
Acute anxiety
Acute psychosis
Agitation:behavioral emergency
Bipolar disorder
Conversion disorder
Major depressive episode
Neuroleptic malignant syndrome
Suicidal ideation and attempt
Musculoskeletal and Rheumatologic Presentations
Acute low back pain (mechanical)
Bursitis
Cervical radiculopathy
Costochondritis
Gout (acute)
Lumbar radiculopathy
Pseudogout
Tendinitis
Dermatology Presentations
Acute eczema (Eczema acute flare)
Allergic contact dermatitis
Erythema multiforme
Henoch-Schönlein purpura
Pressure injury
Psoriasis (acute flare)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria (acute)
Environmental and Exposure Presentations
Envenomation (snake, spider, insect)
High-altitude illness
Hypothermia
Hematologic and Oncologic Presentations
Acute chest syndrome
Coagulopathy
Hyperviscosity syndrome
Sickle cell crisis (vaso-occlusive)
Symptomatic anemia
Thrombocytopenia (severe)
Tumor lysis syndrome
Pediatric-Specific Presentations
Bronchiolitis
Croup
Emergency delivery
Febrile seizure
Kawasaki disease
Neonatal jaundice
Neonatal sepsis
Nursemaid's elbow
Pediatric fever 0 to 28 days
Pediatric fever 29 to 60 days
Pediatric fever 61 to 90 days
Pyloric stenosis
Slipped capital femoral epiphysis
Intussusception
Endocrine and Metabolic Presentations
Adrenal crisis
Diabetic ketoacidosis
Hypercalcemia
Hyperosmolar hyperglycemic state
Hypertensive emergency
Hypertensive urgency
Hypoglycemia
Myasthenia gravis crisis
Myxedema coma
Severe hyperkalemia
Severe hyponatremia
Thyroid storm
ENT and Maxillofacial Presentations
Acute laryngitis
Acute otitis media
Acute pharyngitis
Cerumen impaction
Epistaxis (anterior)
Nasal foreign body
Otitis externa
Tympanic membrane perforation
Ophthalmologic Presentations
Acute angle-closure glaucoma
Central retinal artery occlusion
Chemical eye injury
Corneal abrasion
Corneal ulcer
Globe rupture
Ocular foreign body
Orbital cellulitis
Retinal detachment
Obstetric Presentations
Hyperemesis gravidarum
Painful vaginal bleeding in pregnancy
Placenta previa
Placental abruption
Preeclampsia:eclampsia
Preterm labor
Threatened:inevitable:incomplete abortion
Systemic and Miscellaneous Presentations
Anaphylaxis
Angioedema
Cannabis-induced hyperemesis
Nephrotic Syndrome Flare
POCUS
Procedures
Calculators
Resuscitation
ECG Guide
Back
Clinical Assessment Checklist
Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Life-threatening complication recognition
▶
Hypovolemic shock
▶
SBP < 90 mmHg or MAP < 65 mmHg with severe hypoalbuminemia
Tachycardia, cool extremities, poor skin turgor despite edema
Intravascular depletion despite total body sodium excess
Thromboembolic emergency
▶
Pulmonary embolism: acute dyspnea, pleuritic pain, tachycardia
Cerebral venous sinus thrombosis: headache, papilledema, focal deficits
Renal vein thrombosis: flank pain, hematuria, acute proteinuria worsening
Spontaneous bacterial peritonitis
▶
Fever with abdominal pain or guarding in a nephrotic patient
Reported in 1.5 to 16% of relapses
Diagnostic paracentesis if ascites present with fever
Severe AKI
▶
Oliguria or anuria with rising creatinine
Risk highest in adults over 50 with severe hypoalbuminemia
May be diuretic-induced hypovolemia or intrinsic MCD-associated AKI
Resuscitation targets
Volume status differentiation
▶
Clinically overloaded but intravascularly depleted
▶
Avoid aggressive crystalloid; may worsen edema without restoring intravascular volume
IV albumin 25% 1 g/kg over 2 to 4 hours for hemodynamic instability
Monitor closely for pulmonary edema during albumin infusion
Hemodynamic targets in shock
▶
MAP target > 65 mmHg
Heart rate < 100 beats/min
Urine output > 0.5 mL/kg/hour
Oxygen delivery
▶
SpO2 target > 94% unless COPD
Supplemental O2 if PE, pulmonary edema, or massive pleural effusion suspected
Escalation triggers
Immediate escalation criteria
▶
Respiratory failure from massive pleural effusion or pulmonary edema
▶
Supplemental O2, positioning, consider therapeutic thoracentesis
Avoid NIV if vomiting risk present
Refractory hypotension after albumin
▶
Critical care consultation
Vasopressor initiation if septic physiology present
Suspected PE with hemodynamic instability
▶
Immediate CT pulmonary angiography or bedside echocardiography
Anticoagulation initiation: unfractionated heparin IV
Altered mental status
▶
Cerebral venous sinus thrombosis workup: MRV or CT venography
Posterior reversible encephalopathy syndrome (PRES) consideration
Immediate consults
Consultation triggers
▶
Nephrology
▶
All flares require nephrology involvement for immunosuppressive management
Biopsy decisions for atypical or steroid-resistant disease
Hematology
▶
Confirmed or high-suspicion VTE with complex anticoagulation decisions
Infectious disease
▶
Atypical or severe infections in immunosuppressed patients
Critical care
▶
Respiratory failure, refractory shock, or multiorgan dysfunction
History
Presenting symptoms
Edema pattern
▶
Periorbital edema: often first sign, worse in the morning
Lower extremity pitting edema
Scrotal or labial edema
Ascites and abdominal distension
Urinary symptoms
▶
Foamy or frothy urine: often first noticed symptom
Decreased urine output: suggests AKI or hypovolemia
Hematuria: suggests atypical etiology, warrants further investigation
Constitutional symptoms
▶
Fatigue, malaise, weight gain over days to weeks
Dyspnea: pleural effusion or pulmonary edema
Abdominal pain: spontaneous bacterial peritonitis or renal vein thrombosis
Alarm features
High-risk presentations requiring urgent evaluation
▶
Unilateral leg swelling with pleuritic chest pain
▶
DVT/PE: VTE risk up to 27% in adults with NS
Higher risk in membranous nephropathy
Fever with abdominal pain or guarding
▶
Spontaneous bacterial peritonitis: diagnostic paracentesis
Severe headache with neurological changes
▶
Cerebral venous sinus thrombosis
Posterior reversible encephalopathy syndrome (PRES) from hypertension
Albumin < 20 to 25 g/L
▶
Threshold for life-threatening complications
Life-threatening complications occur in 1 to 4% of flares at this level
Relapse characterization
Prior disease course
▶
Number and timing of previous relapses
▶
Infrequent relapse: < 2 relapses within 6 months of initial response
Frequent relapse: >= 2 relapses within 6 months or >= 4 per year
Steroid-dependent: 2 consecutive relapses during steroid taper or within 14 days of stopping
Steroid responsiveness
▶
Steroid-sensitive vs. steroid-resistant (no remission after 8 to 16 weeks of prednisone)
Prior immunosuppressive agents used and response
▶
Cyclophosphamide, CNIs (cyclosporine/tacrolimus), MMF, rituximab
Prior renal biopsy results: MCD, FSGS, membranous nephropathy, other
Relapse triggers and context
Precipitating factors
▶
Antecedent upper respiratory infection
▶
Most common relapse trigger
URI typically precedes relapse by 1 to 2 weeks
Steroid taper or discontinuation
▶
Relapses commonly occur during or within 14 days of stopping steroids
Medication non-adherence to steroids, CNIs, or MMF
Recent infections or sick contacts
Vaccination status: pneumococcal, meningococcal, varicella (in immunosuppressed)
Risk factors for complications
VTE risk factors
▶
Albumin < 25 g/L: primary driver
Membranous nephropathy histology: highest VTE risk
Female sex, BMI >= 30, AKI, sepsis, immobility
IV corticosteroid use during flare
Lupus nephritis as underlying cause
Infection risk factors
▶
Immunosuppressive therapy: steroids, CNIs, cyclophosphamide, rituximab
Urinary losses of IgG and complement components
Functional hyposplenism
Asplenia or prior splenectomy
Past medical and medication history
Comorbidities
▶
Diabetes mellitus: steroid-induced worsening
Hypertension: may indicate secondary glomerulonephritis
Thrombophilia or prior VTE episodes
Baseline renal function and prior creatinine trajectory
Medications contributing to or complicating NS
▶
NSAIDs: can cause NS (interstitial nephritis with MCD) and worsen renal function; avoid during flares
DOACs: albumin binding leads to urinary drug loss; pharmacokinetics unreliable in NS; not recommended per KDIGO/KDOQI
Bisphosphonates, lithium, D-penicillamine: secondary causes of NS
Diuretics: can precipitate hypovolemia and AKI in severe hypoalbuminemia
Family and social history
Family history
▶
Family history of NS or kidney disease: suggests hereditary/genetic forms
Consanguinity: increases likelihood of monogenic NS
Social history
▶
Ability to perform home urine dipstick monitoring
Access to medications and follow-up
Medication adherence support, particularly in pediatric patients
Physical Exam
Vitals and general
Hemodynamic assessment
▶
Blood pressure
▶
Hypertension: suggests secondary glomerulonephritis (lupus, MPGN)
Hypotension: intravascular depletion despite total body fluid excess
Heart rate
▶
Tachycardia: hypovolemia, infection, PE, or pain
Temperature
▶
Fever: SBP, pneumonia, cellulitis, or other infection
Hypothermia: severe sepsis marker
Weight
▶
Compare to documented dry weight; quantify fluid excess in kg
Volume status exam
Intravascular vs. total body fluid assessment
▶
Jugular venous pressure
▶
Elevated JVP with S3: suggests cardiac contribution; evaluate for heart failure overlap
Low or flat JVP despite edema: intravascular depletion
Mucous membranes and skin turgor
▶
Dry mouth and reduced skin turgor despite peripheral edema
Capillary refill
▶
Prolonged > 2 seconds in hypovolemic shock
Edema distribution
Edema pattern characterization
▶
Periorbital edema
▶
Typically worse in the morning
Often first physical sign in children
Lower extremity pitting edema
▶
Grade and extent: ankle vs. knee vs. thigh
Sacral edema
▶
Posterior sacral pad in bedridden or supine patients
Scrotal or labial edema
▶
Can cause significant functional limitation
Ascites
▶
Shifting dullness and fluid wave
Abdominal tenderness or guarding raises concern for SBP
Pulmonary and cardiovascular exam
Respiratory assessment
▶
Breath sounds
▶
Decreased breath sounds at bases: pleural effusion
Crackles: pulmonary edema from albumin infusion or fluid overload
Work of breathing
▶
Accessory muscle use and inability to speak in full sentences
Percussion
▶
Dullness at lung bases: pleural effusion
Cardiac exam
▶
S3 gallop: cardiac dysfunction overlap
New murmur: infective endocarditis in septic presentation
Abdominal exam
Peritoneal signs
▶
Tenderness and guarding: SBP or secondary bacterial peritonitis
Rebound tenderness: peritonitis
Ascites assessment: shifting dullness, fluid wave, bulging flanks
Hepatomegaly
▶
Hepatic congestion from right heart failure or hepatic venous thrombosis
Extremity and skin exam
DVT assessment
▶
Unilateral leg swelling, warmth, erythema, calf tenderness
Wells score calculation for pretest probability
Skin findings
▶
Skin breakdown from severe edema: cellulitis risk
Striae: chronic steroid use
Cushingoid features: moon facies, buffalo hump, truncal obesity from chronic steroids
Neurological exam
Mental status
▶
Altered level of consciousness: cerebral venous sinus thrombosis, PRES, hepatic encephalopathy
Focal neurological deficits
▶
Papilledema: raised intracranial pressure from venous thrombosis
Focal motor or sensory deficits
Differential Diagnosis
Life-threatening diagnoses not to miss
Pulmonary embolism
▶
ICD-10: I26.99
Acute dyspnea, tachycardia, pleuritic chest pain, hypoxemia
VTE risk up to 27% in adults with NS; highest in membranous nephropathy
Spontaneous bacterial peritonitis
▶
ICD-10: K65.2
Fever, abdominal pain, ascites in nephrotic patient
Encapsulated organisms (Streptococcus pneumoniae, E. coli): IgG urinary loss
Cerebral venous sinus thrombosis
▶
ICD-10: G08
Headache, papilledema, focal deficits, seizures
Consider in any nephrotic patient with new neurological symptoms
Renal vein thrombosis
▶
ICD-10: N28.0
Flank pain, gross hematuria, acute worsening proteinuria
Most common in membranous nephropathy
Fluid overload mimics
Heart failure
▶
ICD-10: I50.9
Elevated JVP, S3, BNP elevation, pulmonary crackles
Proteinuria typically subnephrotic (< 3.5 g/day)
Hepatic cirrhosis
▶
ICD-10: K74.60
Stigmata of liver disease, ascites predominant
Low albumin from hepatic synthetic failure, not urinary loss
Hypoalbuminemia from other causes
▶
Malnutrition, protein-losing enteropathy, chronic illness
Cause of edema worsening in known NS
True NS relapse
▶
uPCR >= 2 g/g or dipstick >= 3+ for 3 consecutive days after prior remission
Medication-induced NS
▶
NSAIDs, bisphosphonates, lithium, D-penicillamine
Secondary cause; review medication list
Secondary glomerulonephritis
▶
ICD-10: N05.9
Lupus nephritis: low C3/C4, ANA+, anti-dsDNA+; hematuria and hypertension
Membranoproliferative GN: low C3, hematuria; hepatitis B/C association
IgA nephropathy: episodic hematuria, often following URI
Progression to FSGS
▶
10 to 30% of adults initially diagnosed with MCD may have underlying FSGS on repeat biopsy
Infection-triggered transient proteinuria
▶
Confirm true relapse: >= 3+ on 3 consecutive days required
Transient proteinuria with viral illness can mimic relapse
Laboratory Tests
First-line urinalysis
Urinalysis with microscopy
▶
Dipstick proteinuria: >= 3+ confirms nephrotic-range proteinuria
Hematuria: suggests atypical etiology; consider FSGS, lupus, MPGN
Oval fat bodies and fatty casts: pathognomonic of heavy proteinuria
Red blood cell casts: nephritic-nephrotic overlap; warrants biopsy
Spot urine protein-to-creatinine ratio (uPCR)
▶
>= 2 g/g defines nephrotic-range proteinuria (KDIGO threshold for relapse)
Accurate alternative to 24-hour urine collection in clinical practice
Collect first morning void for greatest accuracy
Serum chemistries
Basic metabolic panel
▶
Serum creatinine and BUN
▶
Baseline comparison essential; rising creatinine defines AKI
AKI may be diuretic-induced hypovolemia or intrinsic (MCD-associated)
Electrolytes
▶
Hyponatremia: exclude pseudohyponatremia from hyperlipidemia first
Fluid restriction if true Na < 130 mmol/L
Hypokalemia: from loop diuretic use; monitor QT interval
Serum albumin
▶
< 25 g/L: significantly increases VTE risk
< 20 g/L: life-threatening complication threshold; 1 to 4% of flares
Severity marker driving decisions on IV albumin, anticoagulation, admission
Hematologic and coagulation tests
Complete blood count
▶
Leukocytosis: infection; leukopenia if on immunosuppression
Hemoconcentration (elevated hematocrit): intravascular depletion marker
Thrombocytosis: reactive; increases thrombotic risk
Coagulation panel
▶
Elevated fibrinogen: acute phase reactant; contributes to hypercoagulability
Elevated factor VIII and von Willebrand factor: thrombotic risk
Reduced antithrombin III: lost in urine; key mechanism of VTE risk
If VTE suspected: D-dimer (high sensitivity, low specificity in NS due to baseline elevation)
Lipid and metabolic panel
Lipid panel
▶
Hypercholesterolemia and hypertriglyceridemia expected during flare
Lipoprotein(a) elevation: additional cardiovascular risk
Mechanism: reduced oncotic pressure stimulates hepatic lipoprotein synthesis
Liver function tests
▶
Albumin synthesis assessment; exclude hepatic contribution
Rule-out labs for secondary causes
Autoimmune workup (if atypical features: hematuria, hypertension, low complement, systemic symptoms)
▶
ANA, anti-dsDNA: lupus nephritis
Complement C3 and C4: low in lupus, MPGN; normal in MCD/membranous
ANCA (MPO/PR3): pauci-immune GN
Anti-GBM antibodies: Goodpasture syndrome
Anti-PLA2R antibodies: membranous nephropathy (70 to 80% sensitivity)
Infectious causes
▶
Hepatitis B surface antigen and anti-HBc: membranous nephropathy association
Hepatitis C antibody: MPGN association
HIV antibody: FSGS (HIVAN) association
ASO titer: post-streptococcal GN if recent pharyngitis
Blood cultures
▶
If febrile or concern for SBP, sepsis, or pneumonia
Monitoring parameters
Serial monitoring during flare
▶
Daily urine dipstick until remission, then at least twice weekly (KDIGO 2025)
Blood pressure and body weight twice weekly during relapse
Repeat serum albumin, creatinine, uPCR at 1 to 2 weeks and at 4 weeks
If on CNIs: drug trough levels; on cyclophosphamide: CBC for myelosuppression
Diagnostic Tests
Scoring Systems
Relapse classification (KDIGO 2021/2025)
▶
Remission: uPCR < 0.2 g/g or dipstick negative/trace for 3 consecutive days
Relapse: uPCR >= 2 g/g or dipstick >= 3+ for 3 consecutive days after remission
Infrequent relapse: < 2 relapses within first 6 months or < 4 per year
Frequent relapse: >= 2 relapses within first 6 months or >= 4 per year
Steroid-dependent: 2 consecutive relapses during steroid taper or within 14 days of stopping
VTE risk assessment
▶
UNC Bleeding Risk Tool (med.unc.edu/gntools/bleedrisk.html)
▶
Weighs VTE risk against bleeding risk for anticoagulation decisions in NS
Recommended by KDIGO 2021 for membranous nephropathy anticoagulation decisions
Wells Score for DVT pretest probability
▶
Score >= 2: high probability; proceed to ultrasound
Score < 2: low probability; D-dimer then ultrasound if positive
PESI score for PE severity
▶
Class I to II: consider outpatient anticoagulation management
Class III to V: inpatient management with close monitoring
Scoring Systems for steroid response
Steroid resistance definition
▶
Children: no complete remission after 8 weeks of prednisone 60 mg/m2/day
Adults: no complete remission after 8 to 16 weeks of prednisolone 1 mg/kg/day
Steroid resistance triggers renal biopsy and genetic testing consideration
MRI
MRI renal and vascular
▶
MR venography (MRV)
▶
Cerebral venous sinus thrombosis: first-line imaging when CT negative but clinical suspicion high
Sensitivity > 90% for dural sinus thrombosis
MRI brain with gadolinium
▶
Posterior reversible encephalopathy syndrome (PRES): T2/FLAIR hyperintensities in parieto-occipital regions
Gadolinium use with caution if eGFR < 30 mL/min/1.73m2: nephrogenic systemic fibrosis risk
MRI abdomen
▶
Renal vein thrombosis detection if CT contrast contraindicated
MRA for renal artery assessment if vasculitis suspected
CT
CT pulmonary angiography
▶
Indication: suspected PE with intermediate to high clinical probability
Sensitivity > 95%, specificity > 95% for PE
Preferred over V/Q scan if CXR abnormal (pleural effusion, pulmonary edema)
Contrast caution: AKI risk; weigh against diagnostic benefit
CT abdomen with IV contrast
▶
Renal vein thrombosis detection: filling defect in renal vein
Renal venous collaterals: pathognomonic of renal vein thrombosis
Ascites characterization if SBP suspected prior to paracentesis
CT head without contrast
▶
Initial imaging if cerebral venous sinus thrombosis or PRES suspected
Normal in 30% of CVST: proceed to CT venography or MRV if normal
CT venography
▶
Alternative to MRV for CVST if MRI not available
High sensitivity for dural sinus occlusion
Ultrasound
Renal ultrasound
▶
Indications: reduced eGFR, hematuria, abdominal pain, concern for structural abnormality
Renal size: enlarged in acute NS; small and echogenic in chronic disease
Echogenicity: increased cortical echogenicity correlates with severity
Hydronephrosis exclusion in AKI workup
Doppler ultrasound of renal veins
▶
Renal vein thrombosis: absent or reversed Doppler flow in renal vein
Sensitivity 50 to 60% for acute renal vein thrombosis; CT or MR venography preferred
Lower extremity venous duplex ultrasound
▶
DVT diagnosis: non-compressibility of vein under probe pressure
Sensitivity 94%, specificity 98% for proximal DVT
Repeat in 5 to 7 days if initially negative with persistent clinical suspicion
Bedside echocardiography
▶
Right heart strain in massive PE: RV dilation, D-sign, TR jet velocity > 2.8 m/s
Volume status assessment: IVC collapsibility index
Pleural effusion quantification and guidance for thoracentesis
Point-of-care thoracic ultrasound
▶
Pleural effusion: anechoic fluid above diaphragm
Pulmonary edema: B-lines > 3 per intercostal space
Guides therapeutic thoracentesis for respiratory distress
Disposition
Admission criteria
Indications for inpatient admission
▶
Hemodynamic instability: hypotension, shock physiology
▶
IV albumin and monitoring required
Respiratory compromise
▶
Massive pleural effusion, pulmonary edema, or suspected PE
AKI
▶
Rising creatinine or oliguria requiring IV fluid management or nephrology
Suspected or confirmed VTE
▶
DVT, PE, renal vein thrombosis, or cerebral venous sinus thrombosis
Suspected serious infection
▶
SBP, sepsis, pneumonia, or invasive bacterial infection
Severe hypoalbuminemia with limited outpatient access
▶
Albumin < 20 g/L with inability to ensure reliable close follow-up
Requirement for IV diuretics or IV albumin therapy
Severe or functionally limiting edema
▶
Tense ascites, respiratory compromise, or scrotal edema limiting mobility
ICU criteria
ICU-level care triggers
▶
Refractory shock not responding to albumin and vasopressors
Respiratory failure requiring mechanical ventilation or HFNC
Massive PE with hemodynamic instability
Severe AKI requiring renal replacement therapy
CVST with cerebral herniation or refractory seizures
Discharge criteria
Copy
Criteria for safe discharge
▶
Stable vital signs and improving edema
Tolerating oral diuretics and corticosteroids
No evidence of AKI, VTE, or active infection
Reliable nephrology follow-up arranged within 1 to 2 weeks
Patient or caregiver able to perform home urine dipstick monitoring
Education on return-to-ER precautions completed
Follow-up planning
Copy
Outpatient follow-up requirements
▶
Nephrology follow-up within 1 to 2 weeks of discharge or steroid initiation
Repeat labs at 1 to 2 weeks and 4 weeks: albumin, creatinine, uPCR
If on steroid-sparing agents: CNI trough levels, CBC, LFTs per protocol
DEXA scan every 12 to 18 months with prolonged or high-dose steroid exposure
Annual ophthalmologic exam for cataracts and glaucoma with chronic steroid use
Treatment
Initial stabilization
Volume management strategy
▶
IV albumin 25% for hypovolemia or hemodynamic instability
▶
Dose: 1 g/kg IV over 2 to 4 hours
Monitor for pulmonary edema during and after infusion
Co-administration with IV furosemide improves diuretic response in resistant edema
Euvolemic patients with significant edema
▶
Loop diuretics first-line: furosemide IV 1 to 2 mg/kg or oral equivalent
Bioavailability reduced in NS due to albumin binding in tubular lumen
BID dosing preferred over once daily for sustained effect
Diuretic therapy
Loop diuretics
▶
Furosemide IV
▶
Starting dose: 40 to 80 mg IV; titrate to clinical response
Ceiling dose: 200 to 400 mg IV per dose in severe resistance
Continuous infusion: 10 to 40 mg/hour for severe diuretic resistance
Bumetanide IV
▶
1 to 2 mg IV; equivalent to furosemide 40 mg
Better oral bioavailability than furosemide in NS
Torsemide oral
▶
10 to 40 mg BID; better oral bioavailability than furosemide
Diuretic resistance strategies
▶
Thiazide add-on for diuretic resistance
▶
Metolazone 2.5 to 10 mg oral; give 2 to 5 hours before loop diuretic
Hydrochlorothiazide 25 to 50 mg oral as alternative
Monitor potassium closely: high risk of hypokalemia
Potassium-sparing diuretics
▶
Spironolactone 25 to 100 mg daily as adjunct
Use cautiously if AKI or hyperkalemia risk
Immunosuppressive therapy for relapse
Adult MCD relapse (KDIGO 2021)
▶
Infrequent relapse
▶
Prednisolone 20 to 30 mg/day until complete remission, then taper
Lower dose than initial treatment may suffice for established MCD
Continue until uPCR < 0.2 g/g or dipstick trace for 3 consecutive days, then taper over 3 to 6 months
Frequent relapse or steroid-dependent disease
▶
Rituximab: 375 mg/m2 IV x1 to 2 doses; 2025 RCT confirmed efficacy for adult FRNS/SDNS (JAMA 2025)
Cyclophosphamide oral: 2 mg/kg/day for 8 to 12 weeks
Cyclosporine: 3 to 5 mg/kg/day in divided doses; target trough 100 to 150 mcg/L
Tacrolimus: 0.05 to 0.1 mg/kg/day; target trough 4 to 8 mcg/L
MMF: 1 to 2 g/day in divided doses
Pediatric relapse (KDIGO 2025)
▶
Initial relapse treatment
▶
Prednisone or prednisolone 60 mg/m2/day (max 60 mg) until complete remission for >= 3 consecutive days
Then 40 mg/m2/day alternate days (max 40 mg) for 4 weeks, then stop
Typical response: 1 to 2 weeks in children (faster than adults)
Frequent relapse or steroid-dependent (KDIGO 2025)
▶
Rituximab: preferred glucocorticoid-sparing agent per updated KDIGO 2025
Cyclophosphamide oral: 2 to 3 mg/kg/day for 8 to 12 weeks (max cumulative dose)
Tacrolimus vs. MMF: 2025 JAMA Pediatrics RCT showed both effective for pediatric FRNS/SDNS
Levamisole: 2.5 mg/kg alternate days; low-cost option in resource-limited settings
CNIs: cyclosporine or tacrolimus with regular monitoring of drug levels and renal function
Supportive pharmacotherapy
Antiproteinuric agents
▶
ACE inhibitor or ARB
▶
Continue during relapse unless hypotensive or AKI present
Antiproteinuric effect: 20 to 50% reduction in proteinuria
Hold if SBP < 90 mmHg, creatinine rise > 30% from baseline, or K > 5.5 mmol/L
Infection prophylaxis
▶
Trimethoprim-sulfamethoxazole prophylaxis with cyclophosphamide or high-dose steroids
▶
TMP-SMX single-strength daily for Pneumocystis jirovecii prophylaxis
Antifungal prophylaxis: fluconazole if high-dose steroids and mucositis risk
Vaccination review: pneumococcal, influenza, meningococcal (hold live vaccines during immunosuppression)
Anticoagulation for VTE
VTE treatment
▶
Confirmed DVT or PE: anticoagulation required
▶
Unfractionated heparin IV if hemodynamically unstable PE or planned procedures
Low molecular weight heparin (LMWH): enoxaparin 1 mg/kg SC BID (standard dosing)
Caution: LMWH dose adjustment needed in AKI (eGFR < 30 mL/min/1.73m2); consider anti-Xa monitoring
Warfarin: target INR 2 to 3; reliable in NS; preferred long-term agent per KDIGO
DOACs: NOT recommended in NS due to albumin binding and unpredictable urinary drug loss (KDIGO/KDOQI)
Duration: minimum 3 to 6 months; longer if persistent nephrotic syndrome
VTE prophylaxis in high-risk patients
▶
Albumin < 25 g/L with additional risk factors: consider prophylactic anticoagulation
Use UNC Bleeding Risk Tool to weigh thrombotic vs. bleeding risk
Mechanical prophylaxis: compression stockings and early mobilization for all admitted patients
Diet and fluid management
Sodium restriction
▶
1.5 to 2 g/day (60 to 90 mmol/day) during active flare
Optimizes diuretic response and edema management
Fluid restriction
▶
Recommended if serum Na < 130 mmol/L (after excluding pseudohyponatremia from hyperlipidemia)
Protein intake
▶
Moderate protein: 0.8 to 1 g/kg/day in adults
Excessive dietary protein does not replace urinary losses and may worsen hyperfiltration
Lipid management
▶
Statin therapy for sustained hyperlipidemia during prolonged or recurrent NS
▶
Evidence for cardiovascular risk reduction in NS is indirect
Special Populations
Pregnancy
Physiologic considerations
▶
NS in pregnancy carries high maternal and fetal risk
▶
Increased risk of preeclampsia, prematurity, IUGR, and fetal loss
Physiologic hypoalbuminemia of pregnancy complicates severity assessment
New-onset nephrotic syndrome in pregnancy
▶
Must distinguish preeclampsia from primary glomerular disease
Preeclampsia: typically after 20 weeks, hypertension, elevated liver enzymes
Renal biopsy: deferred until postpartum if diagnosis uncertain, unless clinically urgent
Treatment modifications in pregnancy
▶
Corticosteroids: prednisolone preferred over prednisone (placental metabolism reduces fetal exposure)
▶
Lowest effective dose; counsel on gestational diabetes risk
ACE inhibitors and ARBs: CONTRAINDICATED in pregnancy (teratogenic)
▶
Use labetalol or nifedipine for hypertension management
Cyclophosphamide: CONTRAINDICATED in all trimesters (teratogenic, mutagenic)
Tacrolimus and cyclosporine: generally considered compatible with pregnancy with close monitoring
MMF: CONTRAINDICATED (teratogenic); switch to azathioprine if steroid-sparing needed
Rituximab: limited data; use only if benefit outweighs risk; avoid in first trimester
Anticoagulation in pregnancy
▶
LMWH preferred over warfarin for VTE treatment in pregnancy
▶
Warfarin crosses placenta: teratogenic in first trimester, hemorrhagic risk in third
Enhanced VTE prophylaxis recommended given additive thrombotic risks
Geriatric
Age-specific considerations in older adults
▶
AKI risk
▶
Higher risk in adults > 50 with severe hypoalbuminemia and MCD
Meyrier et al. 2018: distinct entity of acute-on-chronic kidney injury in older MCD patients
Diuretic use
▶
Increased orthostatic hypotension risk; cautious up-titration required
Higher risk of hyponatremia and hypokalemia with loop diuretics
Infection risk
▶
Impaired immune response compounded by immunosuppression
Lower threshold for blood cultures and empiric antibiotics
Steroid side effects
▶
Increased risk of steroid-induced diabetes, osteoporosis, cataract, and delirium
Bone protection: calcium + vitamin D supplementation; bisphosphonate if prolonged therapy
Minimize cumulative steroid dose; early transition to steroid-sparing agents
Secondary causes more common in older adults
▶
Membranous nephropathy: most common primary cause in adults > 50
▶
Malignancy-associated membranous: exclude solid tumor (lung, GI, lymphoma)
Anti-PLA2R antibody: positive in primary membranous; negative in malignancy-associated
Amyloidosis: AL or AA; serum/urine protein electrophoresis and fat pad biopsy
Diabetic nephropathy: most common secondary cause globally
Medication pharmacokinetics
▶
Reduced renal clearance: LMWH anti-Xa monitoring required
CNI nephrotoxicity risk compounded by age-related GFR decline
Polypharmacy assessment critical to avoid nephrotoxin co-administration
Pediatrics
Epidemiology and natural history
▶
Peak onset: 2 to 6 years of age
Minimal change disease accounts for > 90% of childhood NS
80 to 90% of children with MCD are steroid-sensitive
Approximately 50% of steroid-sensitive children develop frequently relapsing or steroid-dependent disease
Diagnosis of relapse in children
▶
Urine dipstick >= 3+ for 3 consecutive days: diagnostic for relapse (KDIGO 2025)
May be identified by parents performing home dipstick monitoring
SBP from peritonitis: most feared acute complication; Streptococcus pneumoniae most common pathogen
Treatment in children (KDIGO 2025)
▶
Relapse treatment
▶
Prednisone 60 mg/m2/day (max 60 mg/day) until complete remission for >= 3 days
Then alternate-day prednisone 40 mg/m2 (max 40 mg) for 4 weeks
Children typically respond within 1 to 2 weeks
Steroid-sparing agents for FRNS/SDNS (KDIGO 2025 preferential order)
▶
Rituximab: preferred first-line steroid-sparing agent in KDIGO 2025
Tacrolimus vs. MMF: JAMA Pediatrics 2025 RCT showed comparable efficacy for FRNS/SDNS
Cyclophosphamide: 2 to 3 mg/kg/day for 8 to 12 weeks (track cumulative dose)
Levamisole: 2.5 mg/kg alternate days; often used in resource-limited settings
Weight-based dosing principles
▶
Furosemide: 1 to 2 mg/kg/dose IV or oral (max 40 mg initial dose in infants)
Albumin 25%: 0.5 to 1 g/kg IV over 2 to 4 hours for hypovolemia
LMWH: enoxaparin 1 mg/kg SC BID (neonates: 1.5 mg/kg BID); weight-based dosing tables recommended
Growth and steroid side effects in children
▶
Cumulative steroid dose monitoring: impact on linear growth
Bone mineral density: DEXA at baseline if high cumulative steroid exposure anticipated
Ophthalmologic exam: cataracts from chronic steroid use
Background
Epidemiology
Incidence and prevalence
▶
Nephrotic syndrome incidence: 2 to 7 per 100,000 adults per year
Children: 2 to 7 per 100,000 per year; prevalence up to 16 per 100,000
Relapse rates in MCD adults: 70 to 80% experience at least one relapse
Average time to relapse in MCD: approximately 22 weeks after achieving remission
Approximately 50% of steroid-sensitive children develop FRNS or steroid-dependent disease
Histologic distribution
▶
Adults: membranous nephropathy most common primary cause; MCD second
Adults > 50: membranous nephropathy and amyloidosis more prevalent; MCD less common
Children: MCD > 90%; FSGS approximately 7 to 10%
Steroid-resistant NS: FSGS accounts for most cases in adults
Complication epidemiology
▶
VTE: approximately 27% lifetime risk in adults with NS
SBP: 1.5 to 16% of pediatric and adult relapses
AKI: increased risk in older adults with MCD; distinct AKI-on-MCD entity described
Life-threatening complications during flare: 1 to 4% when albumin < 20 to 25 g/L
Mortality
▶
MCD: excellent long-term prognosis with treatment; 10-year renal survival > 90%
FSGS: more progressive; 50% 10-year renal survival without remission
Membranous nephropathy: rule of thirds (spontaneous remission, partial remission, progression)
Pathophysiology
Glomerular filtration barrier disruption
▶
Normal filtration barrier: podocytes, glomerular basement membrane (GBM), endothelium
Podocyte injury: effacement of foot processes; critical in MCD and FSGS
MCD: immune-mediated podocyte dysfunction; circulating permeability factors hypothesized
Loss of anionic charge barrier allows albumin to pass into filtrate
Consequences of massive proteinuria
▶
Hypoalbuminemia: urinary albumin loss exceeds hepatic synthetic capacity
Edema formation: two mechanisms operating simultaneously
▶
Underfill hypothesis: reduced oncotic pressure leads to fluid extravasation; hypovolemia triggers RAAS/ADH
Overfill hypothesis: primary renal sodium retention independent of systemic hemodynamics
Most patients: mixed mechanism; careful volume assessment required
Hyperlipidemia: reduced oncotic pressure stimulates hepatic lipoprotein synthesis; reduced LPL activity
Hypercoagulability
▶
Urinary losses of antithrombin III, protein C, protein S, plasminogen
Elevated fibrinogen, von Willebrand factor, and factor VIII (acute phase reactants)
Platelet hyperactivation from hypoalbuminemia and hyperlipidemia
Immunological basis of relapse
▶
T cell dysregulation: circulating permeability factors from activated T cells implicated in MCD
B cell role: anti-PLA2R antibodies in membranous nephropathy; rituximab targets B cells
Infection-triggered relapse: cytokine surge from URI activates T cells, precipitating podocyte injury
Genetic susceptibility: HLA-DR7 associated with MCD in children
Therapeutic Considerations
Steroid dosing rationale
▶
High-dose prednisolone induces remission in 80 to 90% of steroid-sensitive MCD
Mechanism: anti-inflammatory and immunosuppressive; stabilizes podocyte cytoskeleton
Adult relapse: 20 to 30 mg/day may suffice for established MCD (KDIGO 2021)
Children: higher weight-based dosing required; 60 mg/m2/day until remission
Steroid-sparing strategy rationale
▶
Cumulative steroid toxicity drives need for sparing agents
Rituximab mechanism: depletes CD20+ B cells; reduces T cell co-stimulation indirectly
▶
2025 JAMA RCT: rituximab reduced relapse rate ~5-fold in adult FRNS/SDNS (Isaka et al.)
CNI mechanism: calcineurin inhibition suppresses T cell activation; also stabilizes podocyte actin cytoskeleton
MMF mechanism: inhibits de novo purine synthesis; selective immunosuppression of lymphocytes
Cyclophosphamide: alkylating agent; durable remission but cumulative gonadotoxicity and malignancy risk
Diuretic resistance mechanisms
▶
Hypoalbuminemia reduces tubular secretion of furosemide (albumin-bound delivery)
Increased sodium reabsorption in distal tubule due to aldosterone activation
Solutions: IV albumin co-infusion, BID loop diuretic dosing, sequential nephron blockade with thiazides
Anticoagulation decision framework
▶
Risk-benefit analysis essential: VTE risk vs. bleeding risk
Membranous nephropathy: VTE risk highest; anticoagulation when albumin < 25 g/L common practice
LMWH preferred for acute VTE treatment; warfarin for long-term; DOACs unreliable due to urinary drug loss
Antithrombin III concentrate: considered adjunct in refractory VTE with low AT-III levels (specialist decision)
Patient Discharge Instructions
copy discharge instructions
Copy
Diagnosis and condition explanation
▶
You have been treated for a flare of nephrotic syndrome, a kidney condition causing protein to leak into the urine
This can cause swelling, low blood protein, and increased risk of blood clots and infections
Your kidneys are sensitive and need careful monitoring while you recover
Medications
▶
Take all prescribed medications exactly as directed; do not skip or stop prednisone without your doctor's guidance
Stopping steroids abruptly can cause serious adrenal insufficiency
Take your diuretic (water pill) as prescribed; your doctor may adjust the dose based on your swelling and urine output
If prescribed a blood thinner, take it exactly as directed and attend all INR checks if on warfarin
Avoid NSAIDs (ibuprofen, naproxen, aspirin for pain): can worsen kidney function and cause further protein leak
Avoid dehydration: drink enough fluids to maintain pale yellow urine, but restrict fluids if instructed due to low sodium
Diet instructions
▶
Low-sodium diet: limit salt to 1.5 to 2 grams per day (about one teaspoon total daily)
Avoid processed foods, canned soups, deli meats, and restaurant foods high in sodium
Moderate protein: follow your nephrologist's recommendations; do not eat excessive protein
Weigh yourself daily at the same time each morning before eating
Report weight gain of more than 1 to 2 kg within 2 to 3 days to your care team
Urine monitoring
▶
Check your urine with a dipstick daily until fully in remission, then at least twice per week
A reading of 1+ or less means you may be going into remission; 3+ or 4+ means the relapse is active
Record your results in a diary to share with your nephrologist
Activity
▶
Light activity is encouraged to reduce blood clot risk; avoid prolonged immobility
Avoid vigorous exercise until swelling and proteinuria have resolved
Compression stockings for leg swelling if tolerated
Infection prevention
▶
Wash hands frequently; avoid contact with sick individuals when on immunosuppression
Ensure pneumococcal and annual influenza vaccines are up to date; discuss with your nephrologist before any live vaccines
Report any signs of infection (fever, chills, redness, wound changes) immediately
Return to emergency department immediately if
▶
Sudden shortness of breath or chest pain: possible blood clot in the lungs
One leg is swollen, red, warm, or painful compared to the other: possible deep vein thrombosis
Severe headache, vision changes, confusion, or difficulty speaking: possible blood clot in the brain
Fever above 38.0 degrees Celsius (100.4 F) especially with abdominal pain: possible infection
Little or no urine output, or urine that is very dark or bloody
Rapid weight gain greater than 2 kg in 24 hours despite taking diuretics
Severe dizziness, fainting, or inability to keep medications down
References
Guidelines and key sources
KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
▶
Floege J, Gibson KL, Vivarelli M, et al. Kidney International. 2025
URL: kdigo.org/wp-content/uploads/2025/04/KDIGO-2025-Guideline-for-Nephrotic-Syndrome-in-Children.pdf
Defines relapse, remission, FRNS, SDNS; steroid-sparing hierarchy including rituximab as preferred first-line
KDIGO 2021 Clinical Practice Guideline for Glomerular Diseases
▶
Ronco P, Rovin B, Schiandorf D, et al. Kidney International. 2021
URL: kdigo.org/wp-content/uploads/2024/05/KDIGO-2021-Glomerular-Diseases-Guideline.pdf
Adult NS management; VTE risk assessment; anticoagulation framework; steroid-sparing options
KDOQI US Commentary on KDIGO 2021 Glomerular Diseases Guideline
▶
Beck LH, Ayoub I, Caster D, et al. American Journal of Kidney Diseases. 2023
US-specific guidance on anticoagulation; emphasizes DOAC avoidance in NS
Landmark trials and key studies
Rituximab for Relapsing Nephrotic Syndrome in Adults (JAMA 2025)
▶
Isaka Y, Sakaguchi Y, Shinzawa M, et al. Journal of the American Medical Association. 2025
RCT confirming rituximab efficacy for adult FRNS/SDNS; approximately 5-fold relapse reduction
Tacrolimus or Mycophenolate Mofetil for FRNS/SDNS in Children (JAMA Pediatrics 2025)
▶
Wang J, Liu F, Yan W, et al. JAMA Pediatrics. 2025
Comparable efficacy of tacrolimus vs. MMF for pediatric FRNS/SDNS
Interventions for Minimal Change Disease in Adults With Nephrotic Syndrome (Cochrane 2022)
▶
Azukaitis K, Palmer SC, Strippoli GF, Hodson EM. Cochrane Database Systematic Reviews. 2022
Evidence review for steroid dosing and steroid-sparing agents in adult MCD
Secondary references
Childhood Nephrotic Syndrome (Lancet 2023)
▶
Vivarelli M, Gibson K, Sinha A, Boyer O. Lancet. 2023
PMID: 37659779
Comprehensive pediatric NS review: epidemiology, triggers, complications, treatment
Acute Kidney Injury Complicating Nephrotic Syndrome of Minimal Change Disease (Kidney International 2018)
▶
Meyrier A, Niaudet P. Kidney International. 2018
PMID: 29980292
AKI-on-MCD in adults: pathophysiology, risk factors, management
Risk Factors of Venous Thromboembolism in Nephrotic Syndrome (NDT 2020)
▶
Shinkawa K, Yoshida S, Seki T, Yanagita M, Kawakami K. Nephrology Dialysis Transplantation. 2020
PMID: 32658957
VTE incidence 27% in adults; key risk factors identified
Idiopathic Nephrotic Syndrome in Children (Lancet 2018)
▶
Noone DG, Iijima K, Parekh R. Lancet. 2018
PMID: 29910038
Epidemiology, pathophysiology, FRNS/SDNS management
Nephrotic Syndrome: Pathophysiology and Consequences (Journal of Nephrology 2023)
▶
Claudio P, Gabriella M. Journal of Nephrology. 2023
PMID: 37466816
Edema mechanisms, hypercoagulability, hyperlipidemia pathophysiology
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.
← Management Protocols
Home
Management Protocols
Nephrotic Syndrome Flare